Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke | Zendy

Lars Søndergaard | Zendy; Scott E. Kasner | Zendy; John F. Rhodes | Zendy; Grethe Andersen | Zendy; Helle K. Iversen | Zendy; Olav Wendelboe Nielsen | Zendy; Magnus Settergren | Zendy; Christina Sjöstrand | Zendy; Risto O. Roine | Zendy; David HildickSmith | Zendy; J. David Spence | Zendy; Lars Thomassen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke

Author(s) -

Lars Søndergaard,

Scott E. Kasner,

John F. Rhodes,

Grethe Andersen,

Helle K. Iversen,

Olav Wendelboe Nielsen,

Magnus Settergren,

Christina Sjöstrand,

Risto O. Roine,

David HildickSmith,

J. David Spence,

Lars Thomassen

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1707404

Subject(s) - patent foramen ovale , medicine , stroke (engine) , foramen ovale (heart) , cardiology , closure (psychology) , migraine , mechanical engineering , economics , engineering , market economy

The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO closure combined with antiplatelet therapy versus antiplatelet therapy alone on the risks of recurrent stroke and new brain infarctions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research